LT3079666T - Farmacinės kompozicijos, apimančios dimetilfumaratą - Google Patents
Farmacinės kompozicijos, apimančios dimetilfumaratąInfo
- Publication number
- LT3079666T LT3079666T LTEP14809821.3T LT14809821T LT3079666T LT 3079666 T LT3079666 T LT 3079666T LT 14809821 T LT14809821 T LT 14809821T LT 3079666 T LT3079666 T LT 3079666T
- Authority
- LT
- Lithuania
- Prior art keywords
- pharmaceutical compositions
- dimethyl fumarate
- fumarate
- dimethyl
- pharmaceutical
- Prior art date
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title 1
- 229960004419 dimethyl fumarate Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382504 | 2013-12-12 | ||
| PCT/EP2014/076767 WO2015086467A1 (en) | 2013-12-12 | 2014-12-05 | Pharmaceutical compositions comprising dimethyl fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3079666T true LT3079666T (lt) | 2021-03-25 |
Family
ID=49917530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14809821.3T LT3079666T (lt) | 2013-12-12 | 2014-12-05 | Farmacinės kompozicijos, apimančios dimetilfumaratą |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20160310457A1 (enExample) |
| EP (2) | EP3656379A1 (enExample) |
| JP (3) | JP6581088B2 (enExample) |
| KR (2) | KR102353201B1 (enExample) |
| CN (2) | CN114159421B (enExample) |
| AR (1) | AR098746A1 (enExample) |
| AU (2) | AU2014363792B2 (enExample) |
| BR (1) | BR112016012179B1 (enExample) |
| CA (2) | CA2932054C (enExample) |
| CL (1) | CL2016001415A1 (enExample) |
| CY (1) | CY1124336T1 (enExample) |
| DK (1) | DK3079666T3 (enExample) |
| EA (1) | EA201600457A1 (enExample) |
| ES (1) | ES2860551T3 (enExample) |
| HR (1) | HRP20210468T1 (enExample) |
| HU (1) | HUE054408T2 (enExample) |
| IL (2) | IL287109B (enExample) |
| LT (1) | LT3079666T (enExample) |
| MX (2) | MX375144B (enExample) |
| MY (1) | MY179355A (enExample) |
| NZ (2) | NZ720287A (enExample) |
| PH (2) | PH12016501043B1 (enExample) |
| PL (1) | PL3079666T3 (enExample) |
| PT (1) | PT3079666T (enExample) |
| RS (1) | RS61658B1 (enExample) |
| SG (3) | SG10201802815UA (enExample) |
| SI (1) | SI3079666T1 (enExample) |
| SM (1) | SMT202100205T1 (enExample) |
| TW (2) | TWI704915B (enExample) |
| UA (2) | UA120428C2 (enExample) |
| WO (1) | WO2015086467A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| CA2939990C (en) | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| WO2016194004A1 (en) * | 2015-06-01 | 2016-12-08 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical compositions of dimethyl fumarate |
| US10631564B2 (en) | 2015-06-19 | 2020-04-28 | University Of Southern California | Enterically coated microparticle compositions and methods for modified nutrient delivery |
| US10744070B2 (en) | 2015-06-19 | 2020-08-18 | University Of Southern California | Enteral fast access tract platform system |
| WO2017040272A1 (en) * | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| CA3007483C (en) | 2015-12-31 | 2021-12-07 | Zaklady Farmaceutyczne Polpharma S.A. | Process for preparation of an enteric coated granulate comprising dimethyl fumarate |
| EP3407873B1 (en) * | 2016-01-28 | 2024-08-21 | Zaklady Farmaceutyczne Polpharma S.A. | Process for preparation of a granulate comprising dimethyl fumarate |
| WO2017137576A1 (en) * | 2016-02-12 | 2017-08-17 | Universität Zürich | Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum |
| WO2017145036A1 (en) * | 2016-02-25 | 2017-08-31 | Aurobindo Pharma Ltd | Pharmaceutical compositions comprising dimethyl fumarate |
| WO2018234584A1 (en) | 2017-06-23 | 2018-12-27 | Almirall, S.A. | Pharmaceutical compositions comprising dimethyl fumarate |
| JP7000148B2 (ja) * | 2017-12-27 | 2022-01-19 | 日本化薬株式会社 | ダサチニブを有効成分とする医薬組成物 |
| WO2020053218A1 (en) | 2018-09-13 | 2020-03-19 | Almirall, S.A. | Treatment of psoriasis |
| WO2020053219A1 (en) | 2018-09-13 | 2020-03-19 | Almirall, S.A. | Treatment of psoriasis |
| AU2020283238B2 (en) * | 2019-05-31 | 2022-07-07 | Curacle Co., Ltd. | Enteric tablet containing dimethyl fumarate |
| JP6744518B1 (ja) * | 2019-11-07 | 2020-08-19 | 旭化成株式会社 | セルロース組成物及び錠剤 |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
| KR20220133807A (ko) * | 2021-03-25 | 2022-10-05 | 주식회사 큐라클 | 특정 약동학적 매개변수를 나타내는 디메틸푸마레이트를 유효성분으로 함유한 약학적 조성물 |
| WO2022212893A1 (en) * | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| US20240374632A1 (en) * | 2023-05-11 | 2024-11-14 | Yon Doo Ough | Apparatus and Method for Contact Free Delivery and Administration of Magnesium as a Drug |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959389A (en) | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| ES2525497T3 (es) | 2004-10-08 | 2015-10-09 | Forward Pharma A/S | Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico |
| CN101056624A (zh) * | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| US20060246128A1 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Micronized tanaproget and compositions containing same |
| CN101304732A (zh) * | 2005-10-07 | 2008-11-12 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| US20080299196A1 (en) * | 2005-10-07 | 2008-12-04 | Aditech Pharma Ab | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester |
| WO2007042035A2 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| WO2009118764A1 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Pharmaceutical composition comprising diclofenac and paracetamol |
| EP2379062A1 (en) | 2009-01-09 | 2011-10-26 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
| DK2379063T4 (da) | 2009-01-09 | 2021-05-25 | Fwp Ip Aps | Farmaceutisk præparat omfattende en eller flere fumarsyreestere i en erosionsmatrix |
| CA2760133A1 (en) | 2009-04-29 | 2010-11-04 | Biogen Idec Ma Inc. | Treatment of neurodegeneration and neuroinflammation |
| CA2835760A1 (en) * | 2011-06-03 | 2012-12-06 | F. Hoffmann-La Roche Ag | Methods of treating mesothelioma with a pi3k inhibitor compound |
| RU2014125430A (ru) | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
| WO2013119677A1 (en) * | 2012-02-07 | 2013-08-15 | Biogen Idec Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
-
2014
- 2014-12-05 SG SG10201802815UA patent/SG10201802815UA/en unknown
- 2014-12-05 EP EP19217154.4A patent/EP3656379A1/en active Pending
- 2014-12-05 US US15/103,465 patent/US20160310457A1/en not_active Abandoned
- 2014-12-05 CA CA2932054A patent/CA2932054C/en active Active
- 2014-12-05 SM SM20210205T patent/SMT202100205T1/it unknown
- 2014-12-05 CA CA3135273A patent/CA3135273A1/en not_active Abandoned
- 2014-12-05 NZ NZ720287A patent/NZ720287A/en unknown
- 2014-12-05 MX MX2016007105A patent/MX375144B/es active IP Right Grant
- 2014-12-05 CN CN202111543717.7A patent/CN114159421B/zh active Active
- 2014-12-05 ES ES14809821T patent/ES2860551T3/es active Active
- 2014-12-05 HR HRP20210468TT patent/HRP20210468T1/hr unknown
- 2014-12-05 SG SG10201913076PA patent/SG10201913076PA/en unknown
- 2014-12-05 UA UAA201607363A patent/UA120428C2/uk unknown
- 2014-12-05 EP EP14809821.3A patent/EP3079666B1/en active Active
- 2014-12-05 AU AU2014363792A patent/AU2014363792B2/en active Active
- 2014-12-05 JP JP2016538622A patent/JP6581088B2/ja active Active
- 2014-12-05 KR KR1020217038861A patent/KR102353201B1/ko active Active
- 2014-12-05 HU HUE14809821A patent/HUE054408T2/hu unknown
- 2014-12-05 NZ NZ759411A patent/NZ759411A/en unknown
- 2014-12-05 IL IL287109A patent/IL287109B/en unknown
- 2014-12-05 LT LTEP14809821.3T patent/LT3079666T/lt unknown
- 2014-12-05 DK DK14809821.3T patent/DK3079666T3/da active
- 2014-12-05 EA EA201600457A patent/EA201600457A1/ru unknown
- 2014-12-05 PT PT148098213T patent/PT3079666T/pt unknown
- 2014-12-05 WO PCT/EP2014/076767 patent/WO2015086467A1/en not_active Ceased
- 2014-12-05 SI SI201431799T patent/SI3079666T1/sl unknown
- 2014-12-05 KR KR1020167015498A patent/KR102335289B1/ko active Active
- 2014-12-05 SG SG10201913080VA patent/SG10201913080VA/en unknown
- 2014-12-05 CN CN201480066692.8A patent/CN105813634A/zh active Pending
- 2014-12-05 UA UAA201906965A patent/UA123880C2/uk unknown
- 2014-12-05 RS RS20210404A patent/RS61658B1/sr unknown
- 2014-12-05 BR BR112016012179-1A patent/BR112016012179B1/pt active IP Right Grant
- 2014-12-05 MY MYPI2016702094A patent/MY179355A/en unknown
- 2014-12-05 PL PL14809821T patent/PL3079666T3/pl unknown
- 2014-12-10 TW TW108144916A patent/TWI704915B/zh active
- 2014-12-10 TW TW103143092A patent/TWI687218B/zh active
- 2014-12-12 AR ARP140104646A patent/AR098746A1/es unknown
-
2016
- 2016-05-17 IL IL245685A patent/IL245685B/en unknown
- 2016-06-01 MX MX2020009745A patent/MX2020009745A/es unknown
- 2016-06-02 PH PH12016501043A patent/PH12016501043B1/en unknown
- 2016-06-09 CL CL2016001415A patent/CL2016001415A1/es unknown
-
2019
- 2019-08-29 JP JP2019156299A patent/JP6945603B2/ja active Active
- 2019-11-19 AU AU2019268075A patent/AU2019268075B2/en active Active
- 2019-11-21 PH PH12019502610A patent/PH12019502610A1/en unknown
-
2021
- 2021-04-27 CY CY20211100359T patent/CY1124336T1/el unknown
- 2021-05-11 US US17/316,861 patent/US20210330628A1/en not_active Abandoned
- 2021-05-25 JP JP2021087768A patent/JP2021130689A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287109A (en) | Pharmaceutical preparations containing dimethyl fumarate | |
| IL290378A (en) | Pharmaceutical compositions containing dimethyl fumarate | |
| IL288961A (en) | Pharmaceutical preparations | |
| IL279395A (en) | A vaccine | |
| PL2943181T3 (pl) | Kompozycje farmaceutyczne | |
| SMT201900684T1 (it) | Composizione farmaceutica combinata | |
| GB201319791D0 (en) | Formulations | |
| ZA201408333B (en) | Pharmaceutical compositions | |
| PL3043778T3 (pl) | Kompozycje farmaceutyczne zawierające refametinib | |
| GB201319792D0 (en) | Formulations | |
| IL245420A0 (en) | New formulations | |
| GB201320432D0 (en) | Novel formulation | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| SG11201509194SA (en) | Radiomitigating pharmaceutical formulations | |
| GB201322948D0 (en) | Improved formulation | |
| GB201317718D0 (en) | Novel formulation | |
| HUP1300496A2 (hu) | Stabil kombinációs gyógyszerkészítmény | |
| IL244365A0 (en) | pharmaceutical preparation | |
| AP2015008890A0 (en) | Pharmaceutical compositions | |
| GB201304699D0 (en) | Pharmaceutical compositions | |
| GB201321497D0 (en) | Pharmaceutical compositions | |
| GB201312851D0 (en) | Pharmaceutical compositions | |
| GB201317717D0 (en) | Novel formulation |